Home
overview

As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.


This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.


It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.
 

ACS Dobfar SpA; Aelin Therapeutics; Akthelia Pharmaceuticals; AMR Centre; Bioharmony Therapeutics; BioVersys AG; Blueberry Therapeutics Ltd; Case Western Reserve University; Centauri Therapeutics; Charles River; Chemical Biology Ventures; Destiny Pharma; Drug Discovery Today; Evotec (UK) Ltd; Evotec UK Ltd; F2G Ltd; Fairy Gut Mother; Genentech; GSK; Helperby; HPRA; King Abdulaziz University; LifeArc; Meiji Seika Pharma Co. Ltd.; Meiji Seika Pharma Co., Ltd.; Morton Findlay Associates Ltd; MycoBiologics at University of Aberdeen; Nektr Technologies; Oxford University; Phico Therapeutics; PSI CRO AG; Russell Publishing Ltd; SCYNEXIS Inc; Therapeutics; TranScrip Partners; University of Birmingham; University Of Liverpool; University of North Texas Health Science Center; Walter Reed Army Institute of Research; Wellcome Trust; WHO; Wollongong Hospital;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

9:10 Exploring new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins

Yuri Gleba

Yuri Gleba, CEO, Nomad Bioscience GMBH
View Bio

• Origins of non-antibiotic antibacterial proteins – a brief history
• A brief summary of the efficacy and potency of bacteriocins
• Methods and approach to bacteriocin expression – plant hosts
• Key commercialisation aspects, challenges and product candidates
 

9:50 Neutralising bacterial virulence effectors: a new paradigm in fighting severe and resistant infections

Samareh Lajaunias

Samareh Lajaunias, Director, Combioxin SA

• Neutralising virulence effectors
• CAL02: agent chemistry and activity
• Showcasing the results of CAL02 randomised, double-blind, multicentre, placebo-controlled trial
• Exploring the current regulatory landscape around neutralisation of virulence factors and beyond
 

10:30 Morning Coffee

11:00 Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

• Analysing the characteristics and benefits of DLAs against drug-resistant pathogens
• A look at the broad-based Gram-negative discovery program that optimises and develops DLA targets
• Explore the Exebacase performance as the only lysin to enter human clinical trials in the US entering phase 3
• Gain insight into the progress of the pipeline: GN Lysins and Amurins
• Evaluating the future outlook of DLA therapeutics
 

11:40 Boosting the antibiotic pipeline through the expansion of portfolio partnerships

Mark Albrecht

Mark Albrecht, Project Officer, HHS/ASPR/BARDA
View Bio

• An outline of the current and prospective antibiotic R&D partnerships
• Hear about BARDA’s contribution to combat antibiotic resistant infections in the US
• Gain insight into biopharmaceutical incubators that facilitate meeting objectives
• Establishing a biopharmaceutical incubator to meet short- and long-term goals
• Explore BARDA funding opportunities
 

12:20 Networking Lunch

13:20 Candida auris: rise of a superbug

Stephen Barat

Stephen Barat, Vice President, Preclinical Research and Early Development, Scynexis
View Bio

• Background, epidemiology and global spread
• Why Candida auris presents a significant cause for concern
• The concern for AMR and the potential utility of new antifungals such as Ibrexafungerp
 

14:00 Immunomodulatory Therapies

Pedro Madureira

Pedro Madureira, CSO, Immunethep
View Bio

• Extracellular Bacterial GAPDH
• Common Virulence Mechanism
• Restore Immune system ability to control infection
 

14:40 Afternoon Tea

15:10 Panel Discussion: The development of non-traditional therapies in ID: known and unknown hurdles

Antonio Perez

Antonio Perez, Chief Medical Officer, Senior Subject Matter Expert, Combioxin SA
View Bio

• What are non-traditional therapies?
• Could efficacy assessments (non-clinical and clinical) used for antibiotics apply to non-traditional agents?
• Are there alternatives to antibiotics or to be administered in combination with antibiotics?
• What are the regulatory guidelines for the development of non-traditional therapies?
• What is the place of non-traditional therapies in terms of financial support and regulatory designations?
• How do non-traditional therapies address the resistance threat?
 

16:10 Chair’s Closing Remarks and Close of Day One

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Michael Dawson

Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy Ltd
View Bio

9:10 Update on the UK project looking at novel value assessment and reimbursement for novel antimicrobials

Colm Leonard

Colm Leonard, Consultant Clinical Adviser to NICE/Consultant Thoracic Physician & Honorary Professor of Medicine, Manchester Academic Health Sciences Centre, NICE
View Bio

• Background to UK project
• Components of UK project
• Progress to date and global context
 

9:50 Evaluating the utility of machine learning and AI in antibiotic drug discovery

Paul Finn

Paul Finn, CEO, Oxford Drug Design
View Bio

• Explore the applicability of machine learning and AI in accelerating antibiotic drug discovery and development
• The technology behind the machine: proprietary 3D ElectroShape technology and the Scopius compound database
• Case study: Aminoacyl tRNA (aaRS) Synthetase Inhibitors
• See the opportunities and challenges that face regulator and clinician acceptance
 

10:30 Morning Coffee

11:00 Preclinical development of metallo-β-Lactamase inhibitor (ANT2681) in combination with meropenem as a potent agent against NDM-CRE

Martin Everett

Martin Everett, Chief Scientific Officer , Antabio

• Worldwide CRE prevalence summary
• Discovery of a novel MBL-inhibitor: ANT431 and reinstating susceptibility
• Progress of the MBLi programme towards a preclinical candidate: ANT2681
• The future of antibiotic adjuvants and combination therapies
 

11:40 Discovery of Dabocins, a novel class of non-β-lactam PBP inhibitors

Francois Moreau

Francois Moreau, Scientific Director, Mutabilis S A
View Bio

• EBL-1463 is a DBO-based covalent inhibitor of Penicillin-Binding Proteins 1a, 2, 3
• It is stable to class A, B, C, D β-lactamases, direct-acting and bactericidal against Enterobacterales
• Overview of MIC profiles and in vivo efficacy against highly resistant MBL-producing CRE
• Early PK/PD and human dose prediction
 

12:20 Networking Lunch

13:20 Highly targeted protein antibiotics for the prevention and treatment of bacterial infections

Daniel Walker

Daniel Walker, Professor of Microbiology, University of Glasgow
View Bio

• Protein antibiotics that show good in vivo efficacy against major Gram-negative pathogens have been identified
• Show extensive distribution into different organs when administered intravenously
• Selective targeting of pathogenic species can be achieved in the complex environment of the intestinal microbiota
 

14:00 Precision biofilm disruption and vaginome editing with phage-based technologies

Lorenzo Corsini

Lorenzo Corsini, Co-Founder, CEO, Research & Development, Phagomed Biopharma GmbH
View Bio

• PhagoMed is an Austrian pre-clinical biotech company focused on developing treatments against persistent, biofilm-associated infections. We will present two of our key assets
• PM-398: PhagoMed’s cocktail of natural, propagating S. aureus phages could transform the standard of care in implant associated infections
• PM-477: PhagoMed’s recombinant, Gardnerella-specific endolysin precisely edits the vaginal microbiome and is being developed for the treatment of bacterial vaginosis
 

14:40 Afternoon Tea

15:10 Inhibition of bacterial cell-wall biosynthesis by carbohydrate scaffolds targeting the glycosyltransferase activity of penicillin-binding proteins

David Roper

David Roper, Professor of Biochemistry and Structural Biology, University of Warwick
View Bio

• Penicillin binding proteins (PBPs) as excellent targets for antibacterials as exemplified by the mode of action of beta-lactams
• Class A PBPs are responsible for the polymerisation of the peptidoglycan precursor, Lipid II into a glycan polymer required for subsequent transpeptidation crosslinking reactions by all PBPs
• Development of a series of sugar base inhibitors of this process with promising in-vitro in-vivo properties of this Class A PBP polymerisation process
• Exploring the mode of action providing a novel perspective on targeting bacterial cell wall biosynthesis
 

16:00 Novel Immunotherapeutics to target Gram-negative bacterial infections

Emma Leire

Emma Leire, Microbiology Lead, Centauri Therapeutics Ltd
View Bio

• Natural antibodies and the discovery of alpha-Gal
• Alphamer platform and how to harness the power of the immune system
• ABX01 mechanism of action in vitro and in vivo
• Translation of immune-recruiting agents in preclinical PK/PD
 

16:40 Chair’s Closing Remarks and Close of Day Two

Michael Dawson

Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy Ltd
View Bio

+

FEATURED SPEAKERS

Antonio Perez

Antonio Perez

Chief Medical Officer, Senior Subject Matter Expert, Combioxin SA
Cara Cassino

Cara Cassino

Chief Medical Officer, ContraFect
Colm Leonard

Colm Leonard

Consultant Clinical Adviser to NICE/Consultant Thoracic Physician & Honorary Professor of Medicine, Manchester Academic Health Sciences Centre, NICE
Francois Moreau

Francois Moreau

Scientific Director, Mutabilis S A
Mark Albrecht

Mark Albrecht

Project Officer, HHS/ASPR/BARDA
Martin Everett

Martin Everett

Chief Scientific Officer , Antabio
Paul Finn

Paul Finn

CEO, Oxford Drug Design
Pedro Madureira

Pedro Madureira

CSO, Immunethep
Samareh Lajaunias

Samareh Lajaunias

Director, Combioxin SA
Stephen Barat

Stephen Barat

Vice President, Preclinical Research and Early Development, Scynexis
Yuri Gleba

Yuri Gleba

CEO, Nomad Bioscience GMBH

Antonio Perez

Chief Medical Officer, Senior Subject Matter Expert, Combioxin SA
Antonio Perez

I hold +31-year in pharmaceuticals including Head of Development of Anti-Infectives at Novartis and Roche´s spin-off, Basilea , in Switzerland; Almirall (Head of Development) and Esteve (Medical Director and Board member), in Spain. In ID I am/was consultant at LASCCO/Combioxin, Eurostars, Abionic, Debiopharm, Kenta Biotech, The Medicines Company, etc). With experience in several C-Boards, Steering committees and worldwide teams, with cross-functional activities with Marketing, Business Development, Finances, Regulatory Affairs, and Research. My projects have been carried out in all continents, from Phase I to IV, having met several Regulatory Agencies (e.g. FDA, EMA, MHRA, PEI, BfArM, Swiss-Medic, ANSM, MPA, AEMPS).

 

Cara Cassino

Chief Medical Officer, ContraFect
Cara Cassino

Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including extensive experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and globally. Dr Cassino joined ContraFect Corporation in 2015 and currently serves as Executive Vice President of Research and Development, and Chief Medical Officer. Prior to joining ContraFect, Dr. Cassino served as Senior Vice President at Forest Laboratories, Inc (acquired by Actavis plc, now Allergan plc), where she oversaw Global Clinical Development across 4 therapeutic areas, including Antiinfectives. While at Forest, she was responsible for pre- and post-marketing clinical activities for a portfolio of 35 compounds, and also clinical due diligence for M&A activity including the $2.9 billion acquisition of Aptalis Pharma and the $1.1 billion acquisition of Furiex Pharmaceuticals. Prior to this, Dr. Cassino held a number of senior executive positions at Pfizer, including Global Medical Team Leader of Pfizer's antibacterial franchise which included Zyvox (linezolid) and Medical Development Group VP for Pulmonary Vascular Disease and Rare Diseases. Dr. Cassino also served as Executive Medical Director for the late stage US respiratory franchise at Boehringer-Ingelheim Pharmaceuticals, Inc, and was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at New York University School of Medicine.
Dr. Cassino received her BA, summa cum laude, in Chemistry and Fine Arts from New York University (NYU) where she was elected Phi Beta Kappa, followed by an M.D. from NYU School of Medicine. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital and a fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center. Dr Cassino is Board Certified in both internal medicine and pulmonary medicine.
 

Colm Leonard

Consultant Clinical Adviser to NICE/Consultant Thoracic Physician & Honorary Professor of Medicine, Manchester Academic Health Sciences Centre, NICE
Colm Leonard

Following undergraduate training in Dublin, and post-graduate experience in Dublin, London and Stanford University in California, Professor Leonard was appointed as a Consultant Thoracic Physician in Manchester in October 2000, and is an Honorary Professor of Respiratory Medicine at Manchester Academic Health Sciences Centre. Since 2008 Prof Leonard spends part of his week in the Centre for Health Technology Evaluation at NICE which involves assessing which novel pharmaceutical and MedTech products will benefit from a NICE assessment.
A significant amount of Prof Leonard’s time over the past 3 years has been spent with colleagues in NICE, DHSC and NHS England & Improvement working towards a novel value assessment & reimbursement mechanism for new antimicrobials.
 

Daniel Walker

Professor of Microbiology, University of Glasgow
Daniel Walker

I am currently Professor of Microbiology in the Institute of Infection, Immunity and Inflammation at the University of Glasgow and head a research group focused on the development of targeted protein antibiotics for the treatment of drug-resistant pathogens and precision microbiome engineering. Our work is funded by the Wellcome Trust, MRC, BBSRC and Scottish Enterprise.

David Roper

Professor of Biochemistry and Structural Biology, University of Warwick
David Roper

David Roper is a former MRC Career Development Award fellow at the University of York and now Professor of Biochemistry and Structural Biology at the University Warwick. The Roper group uses structural biology techniques, principally X-ray structural determination, in combination with molecular biology and biochemical approaches, to investigate the molecular basis of microbial physiology in relation to antimicrobial resistance. Research areas include bacterial cell wall (peptidoglycan) biosynthesis and cell division, antibiotic resistance signaling systems as well as novel approaches to targeting tRNA synthetases in bacterial pathogens. His research encompasses fundamental and translation approaches including assay development and drug discovery approaches.

Emma Leire

Microbiology Lead, Centauri Therapeutics Ltd
Emma Leire

Emma Leire is the Lead microbiologist at Centauri Therapeutics responsible for the in vitro and in vivo microbiology and immunology for the antibacterial projects. Emma completed a joint PhD from University of Nottingham, UK and University of Santiago de Compostela, Spain in nanomedicine 2016 through NANOFAR Erasmus Mundus Fellowship. Her thesis work included synthesis of novel dendritic scaffolds for antibacterial applications and studying the impact of dendrimer generations on anti-adhesion, quorum sensing and membrane permeability. Emma has been a visiting scholar at the University of California, San Diego (UCSD) studying the impact of innate immunity on pathogenesis, and has worked as a researcher at diagnostic company LifeAssays, Sweden, developing tests for inflammatory biomarkers. She earned a BSc in Molecular Biology from University of Lund, Sweden and a MSc in Pharmaceutical Sciences from University of Copenhagen, Denmark.

Francois Moreau

Scientific Director, Mutabilis S A
Francois Moreau

François Moreau has over 20 years’ experience in drug discovery. After a PhD in bioorganic chemistry, he joined Pfizer in 1998 as group leader in enzymology for the therapeutic area Allergy /Respiratory diseases. At Mutabilis in 2004, he contributed to the identification and characterization of bacterial antivirulence drugs designed against LPS heptosylation and teichoic acids D-Alanylation pathways. He also contributed to the development of a new class of antibacterials, the FabI inhibitors and of a new class of antiretrovirals, the allosteric inhibitors of HIV integrase. François is co-author of 25 articles and co-inventor of 15 patents.

Lorenzo Corsini

Co-Founder, CEO, Research & Development, Phagomed Biopharma GmbH
Lorenzo Corsini

Lorenzo is Co-founder | CEO| Research & Development of PhagoMed, a biotech company developing pharmaceuticals to treat bacterial infection based on bacteriophages and endolysins. From 2008 to 2017, he worked for the Boston Consulting Group. In his latest function as a Principal, he was advising pharmaceutical companies on topics ranging from corporate strategy to efficiency and quality in manufacturing, and leading large teams of consultants across multiple projects. Previously, he did his PhD at EMBL Heidelberg, studying pre-mRNA splicing with NMR and X-ray crystallography. Lorenzo has diploma degrees in biochemistry and business administration.

Mark Albrecht

Project Officer, HHS/ASPR/BARDA
Mark Albrecht

Dr. Mark Albrecht joined the Biomedical Advanced Research and Development Authority (BARDA) in March 2012. As the Chief of the Antibacterials Branch, he manages and provides strategic oversight of a complex portfolio of antibacterial development programs with the goal of advancing these candidates through late stage development to potentially achieve FDA marketing authorization and commercialization. Dr. Albrecht works across the U.S. Government and internationally to strengthen inter-agency collaborations, coordinate efforts, and ensure agency portfolios are properly aligned. Prior to joining BARDA, Dr. Albrecht was a Senior Staff Scientist at the Biological Defense Research Directorate (BDRD) within the Naval Medical Research Center (NMRC) were he was responsible for leading the Navy’s programs on passive immune-therapy and the evaluation of multi-valent/agent vaccination strategies based on recombinant proteins and DNA. Dr. Albrecht received his B.A. in Biology from Whitman College in Walla Walla, WA and attended the University of California Riverside where he received his PhD in Microbiology for research on the sensitivity and resistance of Pseudomonas aeruginosa and B. cepacia to antimicrobial peptides and the role of alginate lyase during P. aeruginosa biofilm formation.

Martin Everett

Chief Scientific Officer , Antabio
Martin Everett

Michael Dawson

Director, Mike Dawson Antimicrobial Research Consultancy Ltd
Michael Dawson

Mike has 38 years of drug discovery experience in big pharma and biotech. After 20 years in natural product research with GSK and legacy companies, Mike co-founded Novacta Biosystems. As CSO he led the Company’s C. difficile programme, taking the novel lantibiotic derivative, NVB302, into clinical evaluation. Subsequently as CEO of Cantab Anti-infectives, he led the Company’s polymyxin programme until its acquisition by Spero Therapeutics. Mike is now consulting and is also Head of Biology for Oxford Drug Design. He has authored over 60 papers and is an inventor on over 20 patents.

 

Paul Finn

CEO, Oxford Drug Design
Paul Finn

Paul completed his undergraduate biochemistry degree at St Peter’s College, Oxford and holds a PhD from Manchester University. Paul’s early career was spent in the drug discovery groups at SmithKline Beecham and Pfizer. In 1998, Paul joined Prolifix, subsequently TopoTarget. As Director of R&D Paul was responsible for TopoTarget’s extremely successful HDAC inhibitor programme from which belinostat was approved by the FDA for the treatment of Peripheral T-cell Lymphoma in 2014.
In 2004 Paul moved to Oxford Drug Design, an Oxford University spin-out, which applies novel drug design technology to its pipeline of novel antibacterial projects.

 

Pedro Madureira

CSO, Immunethep
Pedro Madureira

Pedro Madureira is the co-founder and CSO of Immunethep, a biotech company focused on the development of antibacterial immunotherapies.
Pedro Madureira has graduated in Biochemistry at the Faculty of Sciences of the University of Porto (FCUP) and obtained his PhD in Biomedical Sciences at the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) of the same university.
Currently, the main research interest is to understand microbial virulence mechanisms that are responsible to avert host immune system and induce disease. This research led to the development of Immunethep’s immunotherapies, that target an immunosuppressive protein excreted by different multi-resistant bacteria.

 

Samareh Lajaunias

Director, Combioxin SA
Samareh Lajaunias

Stephen Barat

Vice President, Preclinical Research and Early Development, Scynexis
Stephen Barat

Stephen A. Barat, PhD, is currently the Head of Preclinical Research and Early Development for Scynexis. Dr. Barat has more than 20 years of global drug development and registration experience across multiple therapeutic areas. Prior to joining Scynexis, he served in various leadership positions in preclinical development in Allergan, Forest Laboratories, and Schering-Plough. Dr. Barat is also a recognized expert in the interface between safety assessment and CMC requirements and is a member of the PQRI working group for leachables from parenteral drug products and the USP expert panel on biocompatability of packaging materials. He has spoken extensively in numerous international venues on a variety of topics on drug development.

Yuri Gleba

CEO, Nomad Bioscience GMBH
Yuri Gleba

Yuri Gleba has over 45 years of research and management experience in cell genetics and biotechnology.
Yuri’s research was published in more than 220 research papers and over 45 patent families; he is a member of six national and international academies of science.
Yuri managed academic research until 1991 when he joined American Cyanamid Company, Princeton, NJ, as a research director. He left the company in 1999 to become CEO of Icon Genetics, USA/Germany, biotech company he co-founded. Currently he is serving as CEO of Nomad Bioscience, another company he founded in 2008.
 

Sponsors

Supporters

Workshops

Development of non-traditional agents and alternatives to antibiotics
Workshop

Development of non-traditional agents and alternatives to antibiotics

Holiday Inn Kensington Forum
1st April 2020
London, United Kingdom

Anti-microbial resistance and pathogenic fungi
Workshop

Anti-microbial resistance and pathogenic fungi

Holiday Inn Kensington Forum
1st April 2020
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Speaker Interview with Lorenzo Corsini

Download

Superbugs & Superdrugs 2020 Brochure

Download

2020 Full Programme

Download

2020 Conference Speakers

Download

2020 Workshop Programme

Download

Superbugs & Superdrugs Past Attendees List

Download

Past Presentation 2019 - University of Liverpool

Download

Past Presentation 2019 - Blueberry Therapeutics

Download

Past Presentation 2019 - Bioharmony

Download

Past Presentation 2019 - GSK

Download

Past Presentation 2019 - World Health Organisation

Download

Past Presentation 2019 - Summit Therapeutics

Download

Sponsors


SCYNEXIS

Sponsors
http://www.scynexis.com

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

Media Partners


Farmavita

Supporters
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


Global Biodefense

Supporters
http://www.globalbiodefense.com/

Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


International Pharmaceutical Industry

Supporters
http://www.ipimediaworld.com

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


American Pharmaceutical Review

Supporters
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out